CimCure has developed an out-of-the-box way to attack tumours. Its vaccine induces an immune response directed at the tumour vasculature. Eradication of tumour blood vessels and inhibition of their growth will lead to inhibition of tumour growth. Early results were recently published in Nature Communications.
Positron Ventures led the first capital raise, a € 5m investment round in June 2022.
Positron Ventures led the first capital raise, a € 5m investment round in June 2022.
Location: Netherlands, North Holland, Amsterdam
Total raised: $5.36M
Investors 1
| Date | Name | Website |
| - | Positron V... | positron.v... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.06.2022 | Seed | $5.36M | - |
Mentions in press and media 2
| Date | Title | Description |
| 30.12.2022 | Dutch-based biotech and life sciences startups that raised funding in 2022 | The Netherlands is swiftly rising to the top as a hub for healthcare and life sciences innovation. More and more Dutch startups are engaged in a range of cutting-edge initiatives, such as the creation of digital health tools, the developmen... |
| 08.06.2022 | Amsterdam-based cancer vaccine biotech startup CimCure raises €5M | Amsterdam-based CimCure, a biotech company developing vaccine-based cancer immunotherapy, announced on Tuesday that it has raised a little over €5M in a Seed round of funding. CimCure was founded in 2016 as a spin-off from Amsterdam UMC’s T... |